Alpha 2.0
Login Register
» Articles » PMID: 8471439

Chemotherapy and Survival in Advanced Breast Cancer: the Inclusion of Doxorubicin in Cooper Type Regimens

Overview
Journal Br J Cancer
Specialty Oncology
Date 1993 Apr 1
PMID 8471439
Citations 29
Authors
R P AHern
I E Smith
S R Ebbs
Affiliations
Soon will be listed here.
Abstract

The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.

Citing Articles

Triple negative breast cancer: approved treatment options and their mechanisms of action.

Mandapati A, Lukong K J Cancer Res Clin Oncol. 2022; 149(7):3701-3719.

PMID: 35976445 PMC: 10314854. DOI: 10.1007/s00432-022-04189-6.

The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.

Timm K, Tyler D Cardiovasc Drugs Ther. 2020; 34(2):255-269.

PMID: 32034646 PMC: 7125062. DOI: 10.1007/s10557-020-06941-x.

Reversed lipid-based nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection.

Shen L, Zhang Z, Wang T, Yang X, Huang R, Quan D Drug Deliv. 2017; 24(1):857-866.

PMID: 28549383 PMC: 8241146. DOI: 10.1080/10717544.2017.1330373.

Cardiovascular toxicities from systemic breast cancer therapy.

Guo S, Wong S Front Oncol. 2014; 4:346.

PMID: 25538891 PMC: 4255485. DOI: 10.3389/fonc.2014.00346.

Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer.

Mirzaei H, Sabet Rasekh P, Nasrollahi F, Sabet Rasekh P, Akbari Tirabad Z, Moein H Int J Breast Cancer. 2013; 2013:404396.

PMID: 24187626 PMC: 3800644. DOI: 10.1155/2013/404396.

References
1.
CUMMINGS F, Gelman R, Horton J . Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol. 1985; 3(7):932-40. DOI: 10.1200/JCO.1985.3.7.932. View
2.
Smalley R, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S . A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983; 3(2):209-20. DOI: 10.1007/BF01803563. View
3.
Thompson S, Pocock S . Can meta-analyses be trusted?. Lancet. 1991; 338(8775):1127-30. DOI: 10.1016/0140-6736(91)91975-z. View
4.
Freedman L . The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee. Br J Cancer. 1989; 59(3):396-400. PMC: 2247078. DOI: 10.1038/bjc.1989.79. View
5.
Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A . Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987; 5(10):1523-33. DOI: 10.1200/JCO.1987.5.10.1523. View